Ipsen Withdraws Cancer Drug Tazverik Due to Safety Concerns

Ipsen announced Monday it is voluntarily withdrawing its Tazverik cancer drug from all markets after emerging data showed risks may outweigh benefits due to secondary hematologic malignancies.

• “While this is an extremely disappointing outcome, the safety of patients remains our priority”, said Christelle Huguet, PhD & EVP Head of R&D at Ipsen. “Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation”
• Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma and epithelioid sarcoma
  • Ipsen’s decision to withdraw is based on emerging data from the ongoing ...